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Background: DepoVaxTM is a novel non-emulsion depot-forming vaccine platform with the capacity to significantly
enhance the immunogenicity of peptide cancer antigens. Naturally processed HLA-A2 restricted peptides presented
by breast, ovarian and prostate cancer cells were used as antigens to create a therapeutic cancer vaccine, DPX-
0907.
Methods: A phase I clinical study was designed to examine the safety and immune activating potential of DPX-
0907 in advanced stage breast, ovarian and prostate cancer patients. A total of 23 late stage cancer patients were
recruited and were divided into two dose/volume cohorts in a three immunization protocol.
Results: DPX-0907 was shown to be safe with injection site reactions being the most commonly reported adverse
event. All breast cancer patients (3/3), most of ovarian (5/6) and one third of prostate (3/9) cancer patients
exhibited detectable immune responses, resulting in a 61% immunological response rate. Immune responses were
generally observed in patients with better disease control after their last prior treatment. Antigen-specific responses
were detected in 73% of immune responders (44% of evaluable patients) after the first vaccination. In 83% of
immune responders (50% of evaluable patients), peptide-specific T cell responses were detected at ≥2 time points
post vaccination with 64% of the responders (39% of evaluable patients) showing evidence of immune persistence.
Immune monitoring also demonstrated the generation of antigen-specific T cell memory with the ability to secrete
multiple Type 1 cytokines.
Conclusions: The novel DepoVax formulation promotes multifunctional effector memory responses to peptide-
based tumor associated antigens. The data supports the capacity of DPX-0907 to elicit Type-1 biased immune
responses, warranting further clinical development of the vaccine. This study underscores the importance of
applying vaccines in clinical settings in which patients are more likely to be immune competent.
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Cancer immunotherapy has demonstrated clinical bene-
fit in recent clinical trials [1-4]; however, in order to
achieve greater efficacy, several challenges must be
addressed. These include, i) poor immunogenicity of the
chosen peptides and/or vaccine platforms, ii) inappropri-
ate functional polarity of induced responder T cells, iii)
inefficient trafficking into or poor integrity of specific T
effector cells within the tumor microenvironment, iv)
presence of tumor induced immune regulatory cells and v)
suboptimal patient selection and integration with standard
of care treatments. We sought to develop a vaccine strat-
egy to address many of these challenges.
Our novel cancer vaccine DPX-0907 contains a
polynucleotide-based adjuvant and a universal T helper
peptide, along with seven HLA-A2 restricted peptides
derived from tumor-associated antigens. These antigens
are involved in multiple, critical cancer pathways such as
tissue invasion and metastasis (P5; Integrin β8 subunit
precursor, P14; Junction plakoglobin and P15; EDDR1),
evading apoptotic cell death (P3; BAP31) and providing
the ability to resist anti-growth signals (P7; Abl binding
protein C3) [5-9], with resultant specific immune
responses expected to reduce the chance for progression
of tumor escape variants [9,10]. These peptides were
among 16 described using mass spectrometry analysis of
HLA-A2-bound peptides from HLA-A2+ ovarian cancer
cell lines [5]. We have previously described and tested
this vaccine candidate in preclinical models [5,11]. The
vaccine-incorporated peptides are presented by MHC
class I on the cell surface of breast, ovarian and prostate
cancer cells, but not on normal cells [6]. Their inclusion
in DPX-0907 yields an immunogenic vaccine in HLA-
A2 transgenic mice that promotes the activation of both
Type 1 T cell responses, while minimizing the induction
of regulatory mechanisms [11].
In order to enhance the potency of a peptide platform,
we developed a novel vaccine platform called DepoVaxTM
[11], a liposome-in-oil platform containing stable compo-
nents that does not require creation of an emulsion, sim-
plifying the use of oil-based depot vaccines in the clinic.
DepoVax can be custom-formulated with mixtures of
CD8+ T cell peptide epitopes, a T helper epitope derived
from tetanus toxoid [12], and an adjuvant of choice. The
liposomes carry incorporated hydrophilic antigens and ad-
juvant directly into an oil medium such as Montanide
ISA51 VG, entrapping all vaccine ingredients in a form
amenable for efficient uptake and processing/presentation
by antigen presenting cells (APCs). DepoVax-formulated
vaccines can induce effective immune responses after sin-
gle dose administration [11,13-15]. In the current report,
we describe the safety and immunogenicity of a phase I
trial of DPX-0907 in HLA-A2+ patients with advanced
breast, ovarian and prostate cancer.Materials and methods
Patient population and trial design
Specific eligibility criteria for each type of cancer were: i)
ovarian cancer: patients with stage III or IV ovarian can-
cer with evidence of a complete or partial response by
radiological imaging after front-line debulking surgery
and platin-based cytotoxic therapy or patients with
metastatic ovarian cancer, clinically or radiologically
stable disease for greater than 3 months after completion
of first-line therapy; ii) breast cancer: patients with stage
IV breast cancer who had received at least one course of
hormonal or cytotoxic therapy for metastatic cancer, had
completed their course of cytotoxic therapy and had
been off therapy with stable disease or better for
≥3 months. Continued hormonal therapy was permitted;
iii) prostate cancer: patients with rising PSAs or
increases in measurable disease after at least one course
of an accepted hormonal therapy and castrate testoster-
one levels (<50 ng/dL) or who had received previous
courses of cytotoxic chemotherapy. Where applicable,
patients with prostate cancer remained on anti-androgen
therapy during the trial. All patients were positive for
the HLA-A2 haplotype and met other standard inclusion
/exclusion criteria with a life expectancy of at least
6 months.
Subjects received three subcutaneous injections of the
DPX-0907 vaccine three weeks apart in the same upper
thigh region, either at 0.25 mL (dose A) or 1.0 mL (dose
B), according to the schedule shown in Additional file 1:
Figure S1. The study was conducted in accordance with
ethical guidelines of the Declaration of Helsinki. The
protocol and patient-informed consent form received
approval by individual Institutional Review Boards and
ethics committees. Written informed consent was
obtained for all patients.
Vaccine formulation
DPX-0907 contained seven MHC class I-presented pep-
tides (P4, P5, P7, P13, P14, P15 and P3 corresponding to
peptides from Topoisomerase II α, Integrin β8 subunit
precursor, Abl-binding protein C3, TACE/ADAM 17,
Junction plakoglobin, EDDR1 and BAP31 respectively)
which were isolated from HLA-A2+ ovarian cancer cell
line (Additional file 2: Table S1) [5]. The vaccine con-
taining these synthetic peptides (Polypeptide Inc.,
formerly NeoMPS, San Diego, CA) and a T helper pep-
tide epitope (modified tetanus toxin peptide, 830-844;
AQYIKANSKFIGITEL; A16L) was formulated in a pro-
prietary DepoVax formulation as described in published
work [11]. The aqueous liposomal solution was sized to
120 nm particle size through extrusion, lyophilized and
shipped to clinical sites along with a vial of Montanide
ISA51 VG (SEPPIC, France) and the clinical kits were
stored at 4°C until use. Just before use, the lyophilized
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for injection.
Immune monitoring
DPX-0907-induced immune responses in the peripheral
blood of vaccinated patients were investigated at baseline
(SD0) and following each of the three doses administered
(SD21, three weeks after first dose; SD42, three weeks
after second dose; SD73, a month after third and final vac-
cination). Peripheral blood mononuclear cells (PBMC)
were frozen in liquid nitrogen tanks and were shipped in
batches to National Immune Monitoring Laboratory or
NIML, (Montreal, QC) for immunological assessment.
Pentamer staining
The following Pro5W MHC-pentamers conjugated to PE
were purchased from ProImmune (Oxford, UK):
A*0201–NLVPMVATV (CMV), A*0201–SLYNTVATL
(HIV), A*0201–FLYDDNQRV (P4), A*0201-YLIELIDRV
(P13), A*0201–NLMEQPIKV (P14), A*0201–FLAE-
DALNTV (P15), A*0201–ALMEQQHYV (P5), A*0201–
ILDDIGHGV (P7) and A*0201-KLDVGNAEV (P3).
PBMC from patients and healthy donors were thawed
and rested overnight (12-18 h) in complete RPMI media
and were analyzed directly (ex vivo) or after in vitro acti-
vation for 10 days in the presence of individual peptides
from the vaccine (10 μg/mL from day 0-3 and 5 μg/mL
from day 4-10) and IL-2 (10 IU/mL), IL-15 (10 ng/mL).
The pentamer analysis consisted of staining the PBMC
with pentamer at 4°C, followed by a wash step, and
staining for the surface markers CD3, CD8 and CD45RA
in combination with a cell viability marker. This assay
was validated before patient samples were analyzed and
inter- and intra-assay variations were strictly controlled
using the positive control CMV-pentamer and negative
control HIV-pentamer. The CD3+ T cells were selected
from total live gated cells and were further separated
into CD4 and CD8 T cells. The CD8 T cells were further
analyzed based on CD45RA expression and pentamer
positivity to discriminate between memory and naïve
population. More than two-fold higher frequencies of
pentamer-positive CD8 T cells compared to pre-
treatment baseline values were considered as positive
responders to vaccine treatment. In addition, a staining
frequency value of greater than two standard deviations
above background staining by negative control HIV-
pentamer (range 0.00-0.03%) or CD8 negative cells
(range 0.02-0.06%) were required to consider a sample a
positive response. The limit of detection for this assay is
0.02% frequency of pentamer-specific cells.
Intracellular cytokine staining
Briefly, 106 PBMC, after overnight resting, were stimu-
lated for 1 hour with individual peptides and pools ofpeptides (with and without A16L) in the presence of
anti-CD107a antibodies. Final A16L peptide concentra-
tion was 0.5 μg/mL and stimulations with peptide pool
were done at 1 μg/mL (for each peptide). Experimental
controls included unstimulated PBMC, PMA/Ionomycin
and CEF (CMV/EBV/FLU) peptide pool stimulated
PBMC. Protein secretion inhibitors (GolgiPlug™/Golgi-
Stop™, BD Bioscience) were added after 1 hour of stimu-
lation, and cells were incubated for an additional 5
hours at 37°C and 5% CO2. Following in vitro stimula-
tion, cells were washed and surface stained (CD8, CD27
CD3, CD4, CD45RA, CD107a and viability marker) fol-
lowed by intracellular staining (IFN-γ, TNF-α, IL-17, IL-
2 and IL-4) of fixed/permeabilized cells. For gating, a
standard method was used where live cells were gated
for CD3 positive T cells, and were then gated further to
separate CD4 and CD8 T cells. The CD27 and CD45RA
markers were then used, and cells phenotyped as naïve,
central memory, effector memory and late differentiated
T cells. Each of these populations was tested for intracel-
lular cytokine production following peptide stimulation.
Labeled cells were acquired on a LSR II flow cyt-
ometer using the FACS DiVa software (BD Bioscience)
and analyzed using FlowJo software. Multifunctional
cytokine analysis was performed after stringent gating of
each cytokine positive population. In addition, SPICE, a
data mining software application, was used to analyze
large FlowJo data sets from polychromatic flow cytome-
try and to organize the normalized data graphically. A
positive cytokine response was defined as more than
two-fold increase in the frequency of cytokine secreting
cells following peptide-stimulation compared to corre-
sponding non-stimulated cells. Furthermore, vaccine-
induced changes were considered positive when such
cytokine positive cell frequency was more than two-fold
compared to pre-treatment samples and showed ≥ 0.05%
frequency. The limit of detection of this assay is 0.01%
of responder cells.
IFN-γ ELISpot
IFN-γ ELISpot was performed at Cellular Technology
Limited (Shaker Heights, OH). Patient PBMC or non-
vaccinated healthy control PBMC were plated at 3x105
cells per well in 96 well ELISpot plates. Cells were left
unstimulated or stimulated with a range of indicated in-
dividual peptides (10-100 μg/mL) or with similar con-
centrations of the pooled DPX-0907 peptides for 24 h.
The optimum concentration of peptide for stimulation
in this assay was 25-50 μg/mL. PHA was used as a
positive control stimulus. Antigen-specific induction of
IFN-γ was measured by capturing the cytokine with
plate-bound antibodies followed by developing and
counting the number of spot forming units (SFU) in
each well using automated plate scanner. The limit of
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A total of 23 cancer patients qualified to participate in
the study based on inclusion criteria, and included 13
prostate cancer, 7 ovarian cancer and 3 breast cancer
patients. One of the ovarian cancer patients in the dose
B group discontinued the study due to an unrelated ser-
ious adverse event (SAE) following a single vaccination,
leaving a total of 22 patients with 11 patients in each of
the dosage groups. Details on patient’ age, sex, race, his-
tory and number of previous treatments for all patients
enrolled are summarized in Additional file 2: Table S2.
The prostate cancer patients had a median age of
65 years (range 54-76 years) while breast cancer patients
had a median age of 46 (range 44-61 years) and ovarian
cancer patients had a median age of 49 years (range 48
to 67 years). Of note, most of the patients (16/23, 70%)
had a history of ≥3 anti-cancer treatments (cytotoxic/
hormonal/radiation) and 4 patients (including one pa-
tient who did not complete all three vaccinations) had
received a previous immunotherapy (Avastin/Provenge,
Table 1).
Safety
Of the 22 patients who were vaccinated with the full
cycle (three injections) of DPX-0907, no dose limiting
toxicities (DLTs) were reported. A summary of the
reported adverse reactions that are possibly, probably or
definitely related to the different dose levels of DPX-
0907 treatment is shown in Table 2. The most common
adverse events were grade 1 and 2 injection site indur-
ation and erythema for both dose cohorts. A higher inci-
dence of grade 2 injection site erythema, edema and
pain were observed in patients receiving the 1.0 mL dose
vaccine. Two grade 3 ulcerations and a single grade 3
cellulitis were reported after repeated immunizations
with the 1.0 mL dose in the same vicinity. In one patient,
this ulceration and cellulitis were reported 3 weeks after
the third vaccination, which completely resolved by the
next follow-up visit. In another patient, the ulceration
was noted 6 weeks after the third vaccination, which
improved to grade 1 by the next follow-up visit. At the
6 month follow up, most injection site reactions in
patients had resolved to grade 1. There were no vaccine
related grade 3 or greater adverse events after three
immunizations with the 0.25 mL dose. Overall, four
SAEs unrelated to DPX-0907 were observed including: i)
abdominal pain due to disease progression resulting in
hospitalization and eventually death, ii) pneumonia
resulting in hospitalization, iii) partial bowel obstruction
due to disease progression resulting in hospitalization,and iv) urinary obstruction due to disease progression
resulting in hospitalization. No clinical signs of auto-
immunity were seen in any treated patient.
Clinical results
Since long-term monitoring was not included in the
clinical plan, and only 5 of 22 patients completed the full
6 month follow up visit, the maximum time to progres-
sion period recorded in the study was 8-9 months start-
ing from the day of a patients’ first vaccination (i.e.
SD0). Hence, patients who reached the 6 month follow-
up visit and remained disease free at that time were
assigned a time to progression of >8 to 9 months. A
summary of disease status, treatment history, response
to earlier treatments, and time to progression is sum-
marized in Table 1. During the study period 14 patients
progressed, most of whom had prostate cancer (10 of 14
patients). In addition, one prostate cancer patient died
of progressive disease 3.5 months into this study. Infor-
mation on disease progression is not available for the
remaining two prostate cancer patients since they opted
out of the study. In contrast, disease progression was
reported for 2 of 3 breast cancer patients and only 2 out
of 6 ovarian cancer patients. Based on the favorable re-
sponse to previous treatment, the breast cancer and
ovarian cancer patient populations were less likely to be
compromised immunologically and thus were evaluated
together. Among patients who completed follow up, 1 of
3 breast cancer patients and 4 of 6 ovarian cancer
patients had a time to progression of >8-9 months.
These patients were still within the median progression
free survival period for their previous treatment, thus a
clinical benefit of vaccination cannot be ascertained in
this study. Two of the five breast/ovarian cancer patients
were treated in the dose A cohort and three were treated
with the dose B vaccine.
Immune monitoring
An important secondary objective of this trial was to de-
termine the magnitude and diversity of cell-mediated
immune responses induced by vaccination against the 7
cancer-associated peptide epitopes included in DPX-
0907. This was measured primarily by MHC-pentamer
staining for antigen-specific CD8+ T cells and multi-
parametric flow cytometry using the intracellular cyto-
kine staining (ICS) assay. An exploratory ELIspot assay
was performed on select samples. Although a total of 22
patients received the full cycle of vaccinations, the qual-
ity of PBMC and the recovery of cells following thawing
were poor in 4 prostate cancer patient samples, leaving
samples from 18 patients that were deemed ‘evaluable’
for immune analysis.
Due to the relative short duration of the trial and the
limited number of vaccine doses that could be applied to















01-13 44 cytotoxic therapy, hormonal therapy,
immunotherapy (Avastin), radiation
IV SD 0.25 Yes 2 a
04-06 61 concurrent hormonal therapy IV SD 0.25 Yes > 8
04-19 46 cytotoxic therapy, concurrent
hormonal therapy, radiation
IV SD 1.0 Yes 2.5 a
Ovarian Cancer
05-14 50 platinin-based cytotoxic therapy III CR 0.25 Yes 4 a
05-15 48 platinin-based cytotoxic therapy III CR 0.25 Yes 5 a
02-01 49 platinin-based cytotoxic therapy III CR 0.25 No > 9
05-07 54 platinin-based cytotoxic therapy III CR 1.0 Yes > 8
02-09 67 platinin-based cytotoxic therapy,
immunotherapy (Avastin)
IV CR 1.0 Yes > 8.5
01-22 49 platinin-based cytotoxic therapy III CR 1.0 Yes > 8
Prostate Cancer
03-17 60 hormonal therapy, anti-androgen therapy Unknown PD 0.25 Yes 2 a
01-04 67 hormonal therapy, cytotoxic therapy,
anti-androgen therapy, immunotherapy
(Provenge), radiation
IV PD 0.25 No 2 a
02-05 63 ongoing hormonal therapy, cytotoxic
therapy, concurrent anti-androgen therapy
IV PD 0.25 Unknown UE b
03-16 65 hormonal therapy, cytotoxic therapy,
anti-androgen therapy, radiation
IV PD 0.25 No 2.3 a
02-02 66 hormonal therapy, cytotoxic therapy,
anti-androgen therapy, radiation
IV PD 0.25 Unknown 5.7 a
01-03 76 hormonal therapy, anti-androgen
therapy, radiation
IV SD 0.25 No UE b
02-12 54 hormonal therapy, concurrent
anti-androgen therapy, radiation
IV SD 1.0 Unknown 2.3 a
01-18 68 hormonal therapy, anti-androgen
therapy, radiation
IV PD 1.0 Yes 2.3 a
02-20 64 hormonal therapy, anti-androgen
therapy, radiation
IV Unknown 1.0 Unknown 2.3 a
03-21 74 hormonal therapy, anti-androgen
therapy, radiation
IV PD 1.0 No 2.3 a
04-10 63 hormonal therapy, concurrent
anti-androgen therapy, radiation
IV PD 1.0 Yes 3.5 c
03-08 60 hormonal therapy, anti-androgen
therapy, radiation
IV PD 1.0 No 6.5 a
02-11 68 hormonal therapy, anti-androgen
therapy, radiation
IV PD 1.0 No 7.3 a
CR complete response, SD stable disease, PD progressive disease, UE unevaluable.
*since study day 0.
aDisease progression necessitating some other type of treatment.
bWithdrawal of consent.
cDeath due to disease progression.
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to one or more vaccine antigens at one or more of the
time points analyzed post-vaccination. Among the 18
patients evaluable for immune endpoints in this study,the highest frequency of positive immune responses was
observed among the breast and ovarian cancer patients.
All 3 (100%) breast cancer patients and 5 of 6 (83%)
ovarian cancer patients responded to antigens included
Table 2 Safety and reported adverse events, occurring in two or more subjects, which were possibly, probably or
definitely related to DPX-0907 treatment
Toxicity Total No. of Patients 0.25 mL Group 1 mL Group
0.25 mL 1 mL Grade 1 Grade 2 Grade 1 Grade 2 Grade 3
Injection site induration 11 9 6 5 3 5 1
Injection site erythema 8 10 6 2 5 4 1
Injection site pain 3 8 1 2 3 5
Injection site pruritis 3 2 3 1 1
Injection site warmth 2 2 1 1 1 1
Injection site hematoma 2 2
Injection site edema 1 4 1 2 2
Injection site discoloration 1 2 1 2
Injection site rash 1 1 1 1
Injection site urticaria 1 1 1 1
Injection site dry skin 1 1 1 1
Injection site ulceration 3 1 2*
Pain 3 1 2 1 1
Fatigue 2 1 1
Fever 1 2 1 1 1
Arthralgia 1 1 1 1
Myalgia 1 1 1 1
Anaemia 1 1 1 1
*Appeared three or more weeks after of third injection and completely resolved.
Table 3 Immune outcome in DPX-0907-treated patients
Total patients recruited 23
Full treatment received 22
Evaluable 18
Immune response (IR)
Positive IR in: Breast cancer 3/3 (100%)
Ovarian cancer 5/6 (83%)
Breast/Ovarian 8/9 (89%)
Prostate cancer 3/9 (33%)
All patients 11/18 (61%)
Dose A 5/9 (56%)
Dose B 6/9 (67%)
Positive IR after: 1 vaccination 8/11 (73%)
2 vaccinations 2/11 (18%)
3 vaccinations 1/11 (9%)
Positive IR at: 1 time point 2/11 (18%)
2 time points 7/11 (64%)
3 time points 2/11 (18%)
Existing IR at: SD73 7/11 (64%)
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89%. Among prostate cancer patients, 3 of 9 (33%)
showed a positive immune response to vaccination.
Taken together, 11 of 18 patients (61%) showed measur-
able immune responses against one or more of the vac-
cine antigens (Table 3). While two patients’ response
were measurable only by MHC-pentamer testing and 3
patients were positive only using the ICS assay, 6 of 11
patients’ responses were detectable by both the methods
used. Immune responses were detectable as early as
SD21 in 8 of 11 responders (73% or 44% of evaluable
patients) suggesting that just one immunization was suf-
ficient to elicit specific T cell responses in these patients.
In 7 of 11 responders (64%, or 39%, of evaluable
patients), specific response to cancer antigens was
observed at SD73, suggesting the persistence of immune
memory in peripheral blood. The 18 patients evaluable
for immune response were equally split between dose
cohorts (Table 4). Five of 9 0.25 mL (dose A) vaccine
recipients (56%) and 6 of 9 patients (67%) treated with
1.0 mL (dose B) vaccine were categorized as immune
responders.
MHC-pentamer reagents incorporating individual pep-
tides contained in DPX-0907 were used to detect specific
CD8+ T cell responses in patient blood ex vivo or after a
10 day stimulation of T cells in vitro with individual pep-
tides. While most patients required in vitro stimulationof PBMC to expand and detect multimer positive cells,
it was possible to detect such specific T cells ex vivo in
two patients (Table 4). The frequency of ex vivo detected
cells was further expanded following in vitro culture.
Table 4 The Dose A and B vaccine recipients who responded to DPX-0907 vaccination and their immune response to
vaccine antigens
PatientID Cancer Type Vaccine Dosage MHC Pentamer ICS – Flow cytometry
Antigen Positive Study day Positive Positive Stimulus Study day Positive Multi-cytokine Positive
04-06a Breast 0.25 mL P5 P15 21, 42 42 P5 Pool 42 42 Yes Yes
01-13b Breast 0.25 mL None NA Pool 21 Yes
05-14b Ovarian 0.25 mL P4 21, 42 Pool 21, 42c Yes, Noc
05-15b Ovarian 0.25 mL P3 P7 P13 73 73 73 None NA No
03-17b Prostate 0.25 mL None NA Pool 21c, 73 Noc, Yes
04-19b Breast 1.0 mL None NA Pool 42, 73 Yes, Yes
05-07 Ovarian 1.0 mL P15 73 Pool 21 Yes
02-09 Ovarian 1.0 mL P5 P3 42, 73 42 None NA No
01-22b Ovarian 1.0 mL P5 21, 73 Pool 21, 42c, 73c Yes, Noc Noc
04-10a Prostate 1.0 mL P5 P7 P15 21, 42 42 21, 42 P13, P15, Pool 42 42c 42 Yes Noc Yes
01-18b Prostate 1.0 mL P4 P7 42 21, 42, 73 Pool 21c, 42c, 73c Noc, Noc, Noc
aMHC-multimer positive CD8 T cells were also detected ex vivo in these patients: Subject 04-06, P5 (0.12% staining frequency) on SD42; Subject 04-10, P5 on SD21
(0.11%) and on SD42 (0.23%).
bPBMC from these patients were tested against pooled peptides only in ICS assay.
cT cells from PBMC at the indicated study day produced detectable levels of one of the cytokines tested (IFN-γ, TNF-α, IL-2).
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against 6 of 7 tumor-associated peptides (all except P14;
Table 4). The most frequent responses were seen against
peptide P5, followed by P7 and P15. Five of 11 respond-
ing patients (45% or 28% of evaluable patients) were
positive for responses to two or more peptides contained
in DPX-0907.
Among 11 responders in this study, 8 patients (73% or
44% of evaluable patients) were positive in MHC-
pentamer testing, with two-fold or higher increase in the
frequency of specific CD8+T cells compared to baseline
values. In some instances, the increase was >50-fold at
post-vaccination time point compared to SD0 (Add-
itional file 2: Table S3, data shown as fold-increase over
baseline). Due to low level responses seen ex vivo,Figure 1 The generation of antigen-specific CD8+ T cells in DPX-0907
PBMC were stimulated with indicated peptides in vitro as described in Mat
peptide pentamer reagents to detect CD8+ T cells with peptide-specific TC
screened for being HIV negative) and CMV-specific pentamer was used on
assay (data not shown). Samples from all study time points were run simul
percentage of live gated CD3+CD8+ cells that were positive for pentamer s
has been subtracted from the values shown and the values for control HIVin vitro expansion using antigen peptides and cytokines
was necessary in most patients; however, responses seen
ex vivo were reproduced following in vitro activation.
Some patients exhibited pre-existing immune responses
(>two-fold higher than background control) and in some
instances the vaccination stimulated expansion of these
responses (Additional file 1: Figure S2). Sequential
changes in the frequency of antigen-specific T cells at
pre-vaccination baseline and at different post-
vaccination study days are shown in Figure 1. Although
the peak response occurred on different post-vaccination
days for different responders, in almost all patients the
frequency of such cells remained higher at SD73 com-
pared to SD0. Results from three representative respon-
ders identified by the MHC-pentamer assay, withvaccinated ovarian, prostate and breast cancer patients. Patient
erials and Methods. Cells were stained with corresponding MHC-
R repertoire. HIV-pentamer served as a negative control (patients pre-
a known CMV-positive donor PBMC as internal positive control for the
taneously in the assay for each patient. Data represented as
taining. The background staining on CD8 negative cells (0.02-0.06%)
-pentamer staining were in the range of 0.00 to 0.03% for all patients.
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in Additional file 1: Figure S3, with the data representing
actual percentage frequency of CD8+/CD45RA-/multi-
mer+ (antigen-experienced memory) cells.
The ICS assay allows a broader analysis of functionally
relevant antigen-specific T cells following vaccination.
ICS assays were performed with pools of peptides in
most patient samples (n = 10 for pooled peptides and
n= 8 where individual peptides were tested along with
the pool of peptides) due to limited numbers of available
PBMCs. Multi-parametric flow cytometry was performed
on patient PBMC to identify the type of responding T
cells (Total CD8; central and effector memory CD8
cells) along with their ability to simultaneously secrete
Th1 type protective cytokines, namely IFN-γ, TNF-α and
IL-2. The data from cells/peptides from responding
patients have been presented (Tables 4 and 5) and the
data indicate T cells are producing multiple cytokines at
the single cell level. Among eleven immune responders,
nine (82%, or 50% of evaluable patients) were positive in
the ICS assay with a two-fold or higher increase in theTable 5 The generation of multi-functional T cells in patients
Patient ID Indication Vaccine Dosage Antigen- specific
CD8+ T cell popu
04-06a Breast 0.25 mL Total
Total
TCM
01-13a Breast 0.25 mL Total
TCM




03-17 Prostate 0.25 mL Total
04-19 Breast 1.0 mL TCM
TCM
05-07 Ovarian 1.0 mL Total
TCM
01-22a Ovarian 1.0 mL Total
04-10 Prostate 1.0 mL Total
Total
Total




a These patients also showed the presence of IFN-γ secreting TEM cells.frequency of one or more cytokine secreting CD8+ T
cells compared to baseline values (Table 5). Central
memory CD8+ T cells (TCM, CD45RA
-CD27+) were
detected in these patients suggesting that the vaccine
induced antigen-specific memory responses. Cytokine
positive cells were more frequent in the TCM compart-
ment than among total CD8+ T cells (data not shown),
in keeping with previous activation of TCM cells. IFN-γ-
secreting effector memory cells (TEM, CD45RA
-CD27-)
were also detected occasionally (data not shown), but
multi-functional TEM cells were not a significant feature
of the immune responses detected at the specified
timepoints.
Multi-functional T cells expressing IL-2 along with
IFN-γ and TNF-α (Table 5) were detected in some
patients. Three representative cancer patients whose
samples demonstrate increased cytokine secretion fol-
lowing peptide stimulation are shown in Additional file
1: Figure S2.
Multifunctional T cells, as determined by the secre-
tion of more than one cytokine simultaneously, werewho responded to vaccination with DPX-0907
Intracellular cytokine staining
lation Multi-cytokine positivity Cytokines
IFNγ TNFα IL-2
Double + + -
Triple + + +
Double + + -
Triple + + +
Double + + -
Double + + -
Double + + -
Triple + + +
Double + + -
Triple + + +
Double + + -
Double + + -
Triple + + +
Double + + -
Double + + -
Double - + +
Double + + -
Double + - +
Triple + + +
Single + - -
Single - + -
Single - - +
Single + - -
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their total CD8+ and/or CD8+ TCM cell compartments.
Four patients were positive for triple cytokine secreting
multi-functional CD8+ T cells following vaccine treat-
ment. Vaccine dosage did not influence the induction of
multi-functional T cells, but the effect of dose is difficult
to directly ascertain with this small sample size. Two
examples of patients showing multi-functional CD8+ T
cells are shown in Additional file 1: Figure S4. The pres-
ence of triple positive cells, induced only after vaccin-
ation, suggests that DPX-0907 was responsible for
inducing multi-functional, anti-tumor effector cells. In
addition, other cytokines such as IL-17, IL-4 and de-
granulation marker CD107a were also tested in the ICS
assay. While there were no differences seen in the ex-
pression of IL-4 and IL-17 in our patient population
throughout the treatment period, at least four patients
showed expression of CD107a in combination with
IFN-γ, TNF-α or both (data not shown).
As part of the ICS assay, the response of CD4+ T cells
to the T helper epitope (A16L) included in DPX-0907
was also examined. Seventeen of our evaluable patient
samples were tested in total, with nine PBMC samples
tested with A16L alone and PBMC from eight patients
were tested with a pool of DPX-0907 peptides, with or
without the inclusion of A16L. In 13 patients CD4+ T
cell responses were detected by ICS, including multiple
cytokine secretion and four patients were considered
non-responders. Interestingly, two patients exhibited
both pre- and post-vaccination responses to A16L while
11 patients had a CD4 response to A16L post-
vaccination only. In addition, all nine patients who
demonstrated positive cytokine responses in their CD8+
T cell compartment by ICS also displayed positive re-
sponse to A16L in their CD4+ T cell compartment. In
contrast, four patients showed CD4+ T cell responses to
A16L without a concurrent CD8+ T cell cytokine
response.
For most patients, there were insufficient numbers of
PBMCs collected to conduct further confirmatory im-
mune assays. However, for two patients that were con-
sidered immune responders by both pentamer and ICS
assays, there were sufficient PBMC to also test immune
responsiveness using an IFN-γ ELISpot assay. Although
this assay was not a primary portion of the immune
monitoring strategy, it afforded the opportunity to fur-
ther confirm immune responses in these two patients.
The ELISpot confirmed the responses seen in the ICS
assays for both patients (Table 4, Additional file 1: Figure
S5), in that peptides/pools that induced the production
of multiple cytokines in the ICS assay also induced the
production of IFN-γ by ELISpot. Interestingly, an im-
mune response to P13 peptide was detected in the ELI-
Spot assay for patient 04-06, but no such response wasrecorded in the MHC-pentamer assay. Conversely, an
immune response to P4 peptide was detected by the
MHC-pentamer assay for patient 05-14 and not detected
by ELISpot. No non-specific IFN-γ immuno-spots were
seen in non-vaccinated healthy controls PBMC in re-
sponse to DPX-0907 antigens, even at 10-fold higher
antigen concentrations.
Discussion
The purpose of this study was to determine the safety
and immunologic efficacy of DPX-0907, a peptide vac-
cine incorporating a novel carrier and adjuvant formula-
tion. The delivery system, DepoVax, is a liposome-in-oil
platform designed to efficiently entrap hydrophilic anti-
gens and adjuvant directly in the oil medium Montanide
ISA51 VG without the need for emulsification. DepoVax
attracts APCs to the site of vaccination, facilitating anti-
gen cross-presentation in MHC class I to CD8+ T cells
[11]. As a peptide-based vaccine, DPX-0907 has the
advantages of easy manufacture and a favorable safety
profile [16]. The formulation itself has the additional
advantages of long term stability, easy storage and an
easy to use reconstitution method that does not require
emulsification.
The primary endpoint of safety was achieved in this
first-in-man study. Repeated administration of DPX-
0907 did not result in any dose limiting toxicities or ser-
ious adverse events related to vaccine treatment. The
most frequent side effects were grade 1-2 injection site
erythema and induration, consistent with other vaccines
that incorporate Montanide ISA51 VG as the carrier
medium [17-19]. There was no relationship between im-
mune responses and the grade or frequency of site of in-
jection reactions. When 0.25 mL (dose A) is compared
to other vaccines that incorporate antigens in Montanide
ISA51 VG emulsion with a similar oil content, DPX-
0907, not requiring emulsification, results in lower
reports of pain and no reports of grade 3 induration and
swelling [19]. However, we did note greater frequency of
pain and edema, and the presence of grade 3 induration,
erythema and transient ulceration in patients receiving
multiple injections at the dose B (1.0 mL) of DPX-0907.
Though the adverse events seen at the 1.0 mL dose were
largely transient in nature, any further studies with
DepoVax-formulated vaccines will likely contain no
more than 0.5 mL of diluent.
The secondary endpoint was evaluation of antigen-
specific immune responses to DPX-0907. DPX-0907 vac-
cination resulted in the activation of antigen-specific T
cell responses in 61% of evaluable patients. There were
no differences (as measured by the frequency, magnitude
or quality of specific T cell responses) observed in
patients entered on either of the dose tiers (data not
shown), supporting the lack of a vaccine dose/immune
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However, other studies have demonstrated dose
dependent immune responses in patients vaccinated
with peptide antigens [23,24]. This discrepancy may be
related to the antigen, formulation, peptide/protein
length (and subsequent requirement for antigen proces-
sing), adjuvant, vaccination regimen and patient popula-
tion used in these studies. The immune responses in this
study were rigorously documented with state of the art
antigen-specific immune monitoring and consistent
results were generally seen with different immune moni-
toring assays.
DPX-0907 generates rapid and sustained immune
responses [11]. Many patients generated immune
responses after the first vaccination and had detectable
immune responses at two or more time points post DPX-
0907 vaccination. Responses could also be detected for
least one month after the completion of the vaccination
cycle, consistent with our preclinical data. This data com-
pares favorably with other clinical trials in similar patient
populations and was particularly favorable for breast and
ovarian cancer patients. Morse et al [6] recently reported
a phase I cancer vaccine study in ovarian and breast can-
cer patients targeting 12 antigens using MHC class I-
restricted peptides, including the seven peptides used in
DPX-0907 [5,6]. In that study, the peptides were formu-
lated in a highly adjuvanted GM-CSF/Montanide ISA51
VG emulsion. The study demonstrated a 64% (9 of 14
patients) T cell response rate by ELISpot, after 3-10 injec-
tions of vaccine [6]. A similar level of CD8+ T cell
responses was seen in patients with epithelial ovarian
cancer using NY-ESO1 peptides or a mix of tumor asso-
ciated antigen peptides, also following at least 2-5 vacci-
nations [25-27]. DPX-0907 induced a similar immune
response rate with one vaccination (56%) and a higher
immune response rate after three vaccinations (89%) in
similar patient populations. It is not clear in the vaccine
trials mentioned above if these vaccines could generate
immune responses after one vaccination and multi-
functional T cell responses were not documented.
“Multi-functional” T cells, secreting a diverse array of
cytokines in response to cognate antigen, have been in-
creasingly associated with host protection in preclinical
vaccine and tumor immunotherapy models and in HIV-
infected patients [28-31]. Our finding that the majority of
patients responding to DPX-0907 generate such multi-
functional T cells is encouraging and suggests that we may
be generating clinically-relevant immune responses and
that the immunogenic antigens have been combined with
a suitably immunogenic delivery mechanism. DPX-0907
also includes a T helper epitope that has previously used to
augment peptide vaccine immunogenicity [12,25]. Al-
though the focus was to study antigen-specific CD8+ T
cells, CD4+T cell responses werea lso detected against theA16L peptide in vaccinated patients, and these responses
correlated with CD8+ T cell responses in the same assay.
This suggests that the inclusion of a T helper peptide may
have facilitated the generation of the specific CD8 T cells
observed.
All the antigens contained in DPX-0907 are differen-
tially presented by tumor cells [5] and have been vali-
dated experimentally [7,11]. Atleast three antigens (P4,
P5 and P15, representing peptides from topoisomerase
IIa (TOP2A), Integrin β8-precursor, and EDDR1 respect-
ively) have been demonstrated to be upregulated at the
mRNA level in ovarian cancer (unpublished observa-
tions). TOP2A (P4) is also associated with rapidly pro-
gressing cancers and relatively poor survival while
EDDR1 (P15), a protein receptor kinase found to be
over-expressed in ovarian cancers, is associated with
poor prognosis and overall survival [8,32]. In addition,
Tumor necrosis factor-Alpha Converting Enzyme
(TACE/ADAM-17, P13) generates soluble epidermal
growth factor receptor (EGFR) ligands such as EGF and
HB-EGF that have been shown to be important in
tumorigenesis [33].
In our study, we detected immune responses to 6 of
the 7 immunizing antigens (P3, P4, P5, P7, P13 and P15)
contained in DPX-0907. We saw the generation of
responses to multiple antigens in several patients by
MHC-pentamer and ICS assays and were able to con-
firm the observed responses by ELISpot in two respond-
ing patients. Our analysis also demonstrated pre-existing
immune responses to a number of these antigens in our
patient population, which suggests that patients’ T cells
have been primed against these antigens prior to patient
inclusion on this study. This provides further validation
that the chosen vaccine epitopes are biologically relevant
targets. The HLA-A2 restriction of the vaccine is
expected to reduce eligibility of the Caucasian patient
population by 50%, however future vaccines could in-
corporate peptides of other HLA restrictions or more
promiscuous peptides to allow for broader utility of the
vaccine. The multi-antigen approach is expected to
minimize the impact of immune editing of one or more
antigens by cancer cells under targeted immune pres-
sure. The impact of possible HLA down-regulation in
advanced cancer patients on the activity of this vaccine
remains unknown.
Immune responses to DPX-0907 antigens were more
frequent in breast and ovarian cancer patients as com-
pared to prostate cancer patients. It is unclear whether
this result indicates that ovarian and breast cancer
patients are biologically more immune responsive than
prostate cancer patients or whether this reflects other
confounding clinical factors. We note however that most
of the breast and ovarian cancer patients had stable dis-
ease or responses to their previous treatment, whereas
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disease and increasing PSAs. In addition, all prostate
cancer patients entered in this trial had greater than or
equal to three previous treatments and demonstrated
progression necessitating some other treatment soon
after the completion of the three vaccinations. The
observed differences between prostate cancer and other
patients in this study were not statistically significant
due to the small sample size; however, our results indi-
cate that patients with a history of favorable responses
to therapy, in a state of minimal residual disease or with
fewer previous treatments are likely preferred candidates
for treatment with DPX-0907, as has been proposed by
others [34].
In summary, we have shown that this novel cancer
vaccine – DPX-0907 – employing an innovative liposo-
mal formulation is safe, immunogenic and worthy of fur-
ther clinical testing. These studies will likely be required
to optimize the patient populations treated and poten-
tially incorporate an immune modulator to further
optimize the antigen-specific immune responses. Future
strategies will explore this and other antigen vaccines
utilizing the DepoVax formulation, to generate function-
ally relevant clinical response able to reduce or eliminate
micometastatic disease.Additional files
Additional file 1: Figure S1. Clinical protocol outline and dosing
schedule of DPX-0907 for the treatment of breast, ovarian and prostate
cancer patients. Patients were pre-screened for determining their
eligibility to participate in the study and were assigned to dose A or B of
vaccine treatment as indicated. Blood samples were collected at pre-
screening visit, during 3 treatments and at 1, 3 and 6 month post-
treatment follow up. Immune monitoring was performed on PBMC from
SD0, SD21, SD42 and SD73. Figure S2. Antigenic peptide-induced
cytokine secretion by PBMC from DPX-0907 treated breast cancer
patients. Patient PBMC were stimulated ex vivo for 6 h in the presence of
pooled peptides included in DPX-0907, and protein transport inhibitor.
Cells were surface stained for CD3, CD8, CD27 and CD45RA,
permeabilized and stained for intracellular cytokines. Data represent
percentage of total CD8+ T cells and/or central memory (TCM) CD8 T cells
positive for cytokine secretion following peptide stimulation. Figure S3.
Representative pentamer staining dot plots from two ovarian (02-09,
05-15) and one prostate cancer patient (01-18) showing increase in
antigen-specific CD8+ T cells post-DPX-0907 treatment as compared to
base line (SD0). Patient PBMC were stimulated with indicated peptide, in
the presence of cytokines and stained with MHC-pentamer reagents.
Cells were collected using a live gate and CD3+ cells were further
separated to CD8+ T cells. These cells were plotted by CD45RA staining
versus pentamer positive staining. Data on top left quadrant represent
percentage of CD45RAneg/low activated cells that were stained positive for
pentamer reagent prepared using corresponding peptide shown for each
patient. Figure S4. DPX-0907 vaccine induces multi-functional T cells
capable of secreting multiple cytokines. Pre- and post- treatment PBMC
samples from a representative breast (04-06) and ovarian (05-14) cancer
patient were stimulated with peptide pool and analyzed by
multi-parametric flow cytometry. Simultaneous determination of T cell
phenotype (total, TCM) and type of cytokine secreted (IFN-γ/TNF-α/IL-2)
was performed using FACS DiVa software (BD Bioscience) and
multifunctional cytokine analysis was performed after stringent gating ofeach cytokine positive population and subsequent Boolean gating with
FlowJo software. Figure S5. IFN-γ ELISpot responses in DPX-0907-treated
breast and ovarian cancer patient PBMC. PBMC from selected breast and
ovarian cancer patients and from non-vaccinated female healthy control
subjects (HC-1 and HC-2) were used in ELISpot plates to stimulate with
individual and pooled DPX-0907 peptides (10, 25, 50 and 100ug/ml
tested and 50 μg/ml response shown) as described in the Materials and
Methods. Mean ± SD SFU were plotted from the triplicate wells and
expressed per 3x105 cells that were plated per well.
Additional file 2: Table S1. Tumor-associated antigens and
corresponding peptides included in DPX-0907. Table S2. Patient
Demographics. Table S3. Detection of antigen-specific CD8+ T cells in
patients with immune responses to DPX-0907 treatment.
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